home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Harrow, Inc. - Common Stock (NQ:HROW)

41.81 -0.67 (-1.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Harrow, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

March 12, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Harrow Health, Inc. (NASDAQ:HROW) Shareholder Notice: Investigation over Possible Securities Laws Violations ↗

March 08, 2023

San Diego, CA -- (SBWIRE) -- 03/08/2023 -- Harrow Health, Inc. is under investigation over potential securities laws in connection with certain financial statements.

Via SBWire

Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance

March 06, 2023

From Harrow

Via Business Wire

ROSEN, A LEADING LAW FIRM, Encourages Harrow Health, Inc. Investors with Losses to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

March 05, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023

March 02, 2023

From Harrow

Via Business Wire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

February 27, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation - HROW, HROWL, HROWM

February 26, 2023

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

February 24, 2023

From Glancy Prongay & Murray LLP

Via Business Wire

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

February 24, 2023

From Law Offices of Howard G. Smith

Via Business Wire

The Law Offices of Frank R. Cruz Announces Investigation of Harrow Health, Inc. (HROW) on Behalf of Investors

February 23, 2023

From The Law Offices of Frank R. Cruz

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

February 23, 2023

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Harrow Health, Inc. and Encourages Investors with Losses to Contact the Firm

February 22, 2023

From The Schall Law Firm

Via Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Harrow Health, Inc. Investors to Inquire About Securities Class Action Investigation – HROW, HROWL, HROWM

February 22, 2023

From The Rosen Law Firm, P.A.

Via Business Wire

Harrow Launches Next-Generation Compounded Atropine Formulations

February 15, 2023

From Harrow

Via Business Wire

Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023

February 02, 2023

From Harrow

Via Business Wire

Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

January 23, 2023

From Harrow

Via Business Wire

Harrow Announces Availability of Fortisite™ Formulations for In-Office Use

January 05, 2023

From Harrow Health, Inc.

Via Business Wire

10 Health Care Stocks Whale Activity In Today's Session ↗

December 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Melt Pharmaceuticals’ MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study

December 21, 2022

From Melt Pharmaceuticals, Inc.

Via Business Wire

Harrow Secures Capital to Close Recently Announced Acquisition

December 16, 2022

From Harrow Health, Inc.

Via Business Wire

$10 Million Bet On Dyne Therapeutics? Check Out These 4 Stocks Insiders Are Buying ↗

December 15, 2022

Although US stocks closed lower on Wednesday following Fed’s rate decision, there were a few notable insider trades.

Via Benzinga

REV Group, Avidity Biosciences And Some Other Big Stocks Moving Higher On Wednesday ↗

December 14, 2022

U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones

December 14, 2022

From Harrow Health, Inc.

Via Business Wire

Why Netcapital Shares Are Trading Lower By Over 33%? Here Are 50 Stocks Moving In Wednesday's Mid-Day Session ↗

December 14, 2022

Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares rose 153% to $0.3325 after gaining 14% on Tuesday. Crown ElectroKinetics, last month, posted a Q3 loss of $0.18 per share.

Via Benzinga

Harrow Prices $25 Million Offering

December 14, 2022

From Harrow

Via Business Wire

Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE®

December 14, 2022

From Harrow

Via Business Wire

Harrow and iOR Partners Expand National Product Supply Agreement

November 30, 2022

From Harrow

Via Business Wire

Harrow Announces Third Quarter 2022 Financial Results

November 14, 2022

From Harrow

Via Business Wire

Harrow Launches Atropine.com

November 10, 2022

From Harrow

Via Business Wire

Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022

October 28, 2022

From Harrow

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com